Loading
A phase 1/2 trial of serplulimab in colorectal cancer, run by Shanghai Henlius Biotech, not yet recruiting.
A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer is a phase 1/2, randomised interventional study registered as NCT07358585 by Shanghai Henlius Biotech, with a registry enrolment figure of 126 participants, started 2026-01-31 and due to reach its primary completion in 2027-07-28. Interventions recorded: HLX43 dose 1 + HLX07; HLX43 dose 2 + HLX07; HLX43 dose 3 + Serplulimab; HLX43 dose 4 + Serplulimab. Conditions listed: Colon Cancer Adenocarcinoma. Primary outcome: ORR; PFS. Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed advanced or metastatic colorectal adenocarcinoma; and locally tested and confirmed as a RAS/BRAF wild-type tumor (only for Part 1 );". Sites: China. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Serplulimab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Shanghai Henlius Biotech, Serplulimab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Serplulimab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Shares Serplulimab, Colorectal cancer trials open today (registry snapshot), Immune checkpoint inhibitors and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/